Loading
IBI130 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.
ASCO 2025 abstract 1102 reports 71 patients treated in the first-in-human study at the December 15, 2024 cutoff. Among 30 efficacy-evaluable TNBC patients across doses, ORR was 50.0% (95% CI 31.3 to 68.7); PFS and duration of response were immature. Grade 3 treatment-related events occurred in 15.5% of the 71 patients; one had grade 1 interstitial lung disease. This is an uncontrolled early cohort, not comparative proof of improved safety or efficacy.
Anti-TROP2 antibody linked to NT1, a camptothecin-derived TOP1 inhibitor. Connects to TROP2.
1.IBI130's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IBI130" OR ABSTRACT:"IBI130") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IBI130, not a curated reading list.
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/